RUBY Study Survival Analysis Informs Frontline Treatment Selection

Panelists discuss how findings from a post hoc survival analysis of the phase 3 RUBY study provide new insights into treatment outcomes for patients with primary advanced or recurrent endometrial cancer, particularly those with mismatch repair–proficient/microsatellite-stable (pMMR/MSS) disease. They explain that survival trends were analyzed based on both initial and subsequent therapies, offering a more comprehensive view of long-term benefit.

The conversation explores how this subgroup analysis supports the use of dostarlimab plus chemotherapy in a broader population, revealing sustained survival benefit even in patients without mismatch repair deficiency. Panelists also address how these data can guide clinicians in managing older patients, emphasizing considerations such as tolerability, comorbidity, and maintaining quality of life alongside survival outcomes.

In closing, the panel reflects on how these findings inform frontline treatment decision-making and future trial designs. They suggest that understanding the nuanced survival benefits across molecular subtypes will continue to refine personalized immunotherapy strategies for this challenging disease.